Clinical Trial Update: A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating palonosetron for preventing chemotherapy-induced nausea and vomiting in patients who previously experienced CINV during the prior cycle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Disease

Drugs mentioned

• Palonosetron (palonosetron)

Snippet

Sponsor: Eisai Inc. | Conditions: Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC | Phase 2 | Status: COMPLETED | Results posted: 2020-12-23